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Harada disease is a posterior uveitic disease 
manifesting exudative retinal detachment that is 
classified as the posterior uveitis type of Vogt-
Koyanagi-Harada (VKH) syndrome.  Indocyanine 
Abbreviations:  AD, maximum amplitude in the dark period; AL, minimum amplitude in the light period during FO 
measurement;  CRVO, Central retinal vein occlusion;  dfFO, average difference in µV between AD and AL during 
the FO measurement; EOG, electrooculogram; FO, fast oscillation; ICG, indocynine green; L/DSO, light/dark trough 
ratio of the SO; RfFO, average ratio in percentage of AD/AL; SO, slow oscillation;  VKH, Vogt-Koyanagi-Harada 
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We assessed clinical utility of fast and slow oscillations (FO and SO) of the electro-
oculogram (EOG) in Harada disease.  In 12 eyes of 4 female and 2 male subject patients 
aged 18 to 77 years (average: 41.8 years), FO and SO were recorded using an automated 
electrooculograph, the Nidek EOG-2, in the acute period before treatment and in the 
remission period under corticosteroid therapy.  FO parameters, namely the RfFO [the 
average ratio in percentage of the maximum amplitude in the dark period (AD)/the 
minimum amplitude in the light period (AL) during FO measurement] and the dfFO 
(the average difference in µV between AD and AL) were evaluated.  The L/DSO (the light 
peak/dark trough ratio of the SO) was calculated as an SO parameter.  The RfFO, dfFO 
and L/DSO showed low values in 7 (58.3%), 10 (83.3%) and 8 (66.7%) out of all 12 eyes 
in the acute period, respectively.  In the remission period, values in the normal range 
were obtained in 12 (100%), 11 (91.7%) and 8 (66.7%) out of 12 eyes in the RfFO, dfFO 
and L/DSO, respectively.  In mutual relation to each RfFO, dfFO and L/DSO in the acute 
and remission periods, all 12 eyes showed recovery values both in the RfFO and dfFO 
in the remission stage after systemic administration of corticosteroids, but 4 out of 12 
eyes (33.3%) showed no recovery in the L/DSO.  The FO may therefore well reflect the 
affected or ameliorated conditions in the outer layers of the retina and the choroid in 
Harada disease, in contrast to the SO.  However, further observations are requested in 
more Harada disease patients.
Key words:  acute and remission periods; electrooculogram; fast oscillation; Harada disease; slow 
oscillation
green (ICG) fluorescence angiography has revealed 
severe disturbance of choroidal circulation deriv-
ed from compression due to the high-grade infil-
tration of inflammatory cells into the choroid in 
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Harada disease; in the early to late stage, leakage 
from the choroid into the subretinal space is seen 
in ICG angiography at the same leak points seen 
in fluorescein fundus angiography, and in the late 
phase, filling delay of the choroidal circulation 
and indistinct choroidal vessels correlate with the 
severity of the disease (Matsunaga et al., 1994).
        VKH syndrome is considered to be an auto-
immune syndrome against melanocytes (Moorthy 
et al., 1995).  The mechanism and immunological 
reactions against melanocytes are not well under-
stood (Hayakawa et al., 2004), but clinically VKH 
syndrome can be treated relatively easily by system-
ic corticosteroids, although the inflammation may 
be prolonged and result in reduced visual acuity in 
some cases.
        Choroidal circulation supplies the outer por-
tion of the retina, including the photoreceptor cells 
and retinal pigment epithelium.  Thus, it is natural 
that choroidal circulation disturbance should influ-
ence fast and slow oscillations (FO and SO) of the 
electrooculogram (EOG) originating from the outer 
portion of the retina, mainly the retinal pigment 
epithelium under the influence of choroidal circula-
tion (Nakao et al., 1995; Tamai et al., 1997; Inoue 
et al., 2003), but little attention has been paid to 
the behavior of both potentials, especially the FO 
in various types of choroidal diseases including 
Harada disease (Tamai et al., 1997; Tamai, 2003). 
In the present study, we assessed clinical utility of 
the FO and SO of the EOG in Harada disease.
Patients and Methods
Patient selection
Six patients (2 males, 4 females; age range 18–77 
years, average 41.8 years) with Harada disease in 
the acute period before treatment were randomly 
chosen for EOG recording over the past 4 years 
(August 1996 to September 2000) at the Depart-
ment of Ophthalmology, Tottori University Hos-
pital (Table 1).  Both eyes showed typically 
affected diffuse or focal chorioretinal lesions, 
ophthalmoscopically and fluorescein fundus 
angiographically at the initial clinical examination 
in each patient.  All patients were treated by 
systemic corticosteroids with intravenous injection 
of methylpredonisolone 1,000 mg for 3 days 
Table 1.  Clinical data of 12 eyes of 6 patients with Harada disease
Patient        Corrected visual acuity
number Age (year)    Sex  Affected eye        Acute period     Remission period Type of RD
 1 47 Female Right 0.03 1.2 Diffuse
    Left 0.04 0.8 Diffuse
 2 77 Female Right 0.5 0.9 Diffuse
    Left 0.2 0.9 Diffuse
 3 21 Female Right 0.03 1.2 Diffuse
    Left 0.02 1.2 Diffuse
 4 18 Female Right 0.7 1.0 Focal†
    Left 0.7 0.8 Focal
 5 33 Male Right 0.5 1.2 Diffuse
    Left 0.05 1.2 Diffuse
 6 55 Male Right 0.8 1.0 Focal
    Left 0.7 0.9 Focal
 Average   41.8   0.23 0.87
 RD, exudative retinal detachment in the acute period.  
† Limited in the arcade.  
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Table 2.  Results of the RfFO of the EOG in 12 eyes of 6 patients with Harada disease
Patient Affected            Acute period        Remission period
number eye   RfFO (%) <114.7%* RfFO (%) ≥114.7%†   Recovery value§
 1                  Right 108  119  
                    Left 109  121  
 2                   Right 124  139  
                    Left 110  124  
 3                   Right 138  147  
                    Left 127  133  
 4                   Right 114  155  
                    Left 113  150  
 5                   Right 108  135  
                    Left 108  142  
 6                   Right 130  135  
                    Left 128  138  
 Ratio                 7/12 (58.3%)  12/12 (100%) 12/12 (100%)
* Data under 114.7% indicate low values of the RfFO in the present study.
† Data over 114.7% indicate values in the normal range.
§ Increased RfFO obtained in the remission period, compared with the RfFO in the acute period.
 Pertinent data in each column are marked by a solid circle ( ).
followed by gradually decreased administration 
of predonisolone from 60 mg to 5 mg every week 
until the remission stage.
        Their corrected visual acuities from 0.02 to 0.7 
averaging 0.23 in the acute period showed remarkably 
recovered visions from 0.8 to 1.2 averaging 0.87 in 
the remission period under corticosteroid therapy 
(Table 1).
        Patients were excluded from this study if they 
had an opaque media and a bilateral refraction error 
difference of more than 3 diopters.
FO and SO recordings
By a newly devised automated electrooculograph, 
the Nidek EOG-2 (Nidek, Gamagori, Japan) (Nakao 
et al., 1995; Inoue et al., 2003), the FO and SO 
were recorded in the acute period before treatment 
and in the remission period under corticosteroid 
therapy in each patient.  The EOG-2 consists of a 
dome, a personal computer, an index controller, 
an amplifier, a printer and an EOG pen recorder. 
Inside the dome is a hemispheric screen with a 
radius of 300 nm.  Four tungsten lamps (115 V, 50 
W) produce a background luminance of 1,270 lx, 
when measured at the location of the patient’s eyes.
        For every patient, cup-shaped silver-silver 
chloride conductive electrodes, 8 mm in diameter, 
were placed beside both canthi of each eye on the 
orbital margin, and a grounding electrode, with the 
same cup shape, was placed on the left earlobe, as 
routinely used.  Before setting these electrodes, 
the skin was cleaned with 90% alcohol, and then 
electrodes were applied with a conductive paste. 
Electrode resistance was below 10 kΩ.
        Before FO recording, a 10-min adaptation 
period at a background luminance level of 1,270 lx 
was given to the patients.  Then the patients were 
instructed to fixate alternately on a pair of targets on 
the screen inside the dome.  The 2 targets subtended 
40° to the eye, and were presented alternately with 
a frequency of 0.5 Hz.
        On the FO recording, the dome was periodi-
cally illuminated for 1 min followed by 1 min of 
darkness.  The measurements were started 40 s 
after each dark or light period began.  There were 
10 measurements in each dark or light period.  Six 
out of 10 EOG amplitudes were automatically 
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averaged and recorded at the end of each dark or 
light period through the EOG artifact rejection 
system on the Nidek EOG-2 (Inoue et al., 2003).
        In 10 pairs of FO measurements (dark-light 
period of 1 min each), FO parameters, namely 
the RfFO [the average ratio in percentage of the 
maximum amplitude in the dark period (AD)/the 
minimum amplitude in the light period (AL)] and 
the dfFO (the average difference in µV between 
AD and AL during the FO measurement) were cal-
culated, referring to the report by De Rouck and 
Kayembe (1981), only if at least 3 successive steps 
Table 3.  Results of the dfFO of the EOG in 12 eyes of 6 patients with Harada disease
Patient Affected         Acute period          Remission period
number     eye dfFO (µV) <108.4 µV*  dfFO (µV) ≥108.4 µV†  Recovery value§
 1                  Right 55  109  
                    Left 45  124  
 2                   Right 83  181  
                    Left 47  125  
 3                   Right 80  113  
                    Left 78  104  
 4                   Right 124  191  
                    Left 114  144  
 5                   Right 23  210  
                    Left 18  110  
 6                   Right 92  138  
                    Left 101  127  
 Ratio                 10/12 (83.3%)  11/12 (91.7%) 12/12 (100%)
* Data under 108.4 µV indicate low values of the dfFO in the present study.
† Data over 108.4 µV indicate values in the normal range.
§ Increased dfFO obtained in the remission period, compared with the dfFO in the acute period.
 Pertinent data in each column are marked by a solid circle ( ).
Table 4.  Results of the L/DSO of the EOG in 12 eyes of 6 patients with Harada disease
Patient Affected        Acute period     Remission period
number eye L/DSO <1.6* L/DSO ≥1.6† Recovery value§
 1 Right                     1.37  2.14  
  Left                       1.29  2.14  
 2 Right                     2.45  1.96 
  Left                       1.76  1.47
 3 Right                     1.40  3.37  
  Left                       1.34  3.59  
 4 Right                     1.43  1.85  
  Left                       1.44  1.91  
 5 Right                     1.00  1.06  
  Left                       1.30  1.48  
 6 Right                     2.37  1.51
  Left                       2.27  1.68 
Ratio                                 8/12 (66.7%)  8/12 (66.7%) 8/12 (66.7%)
* Data under 1.6 indicate low values of the L/DSO in the present study.
† Data over 1.6 indicate values in the normal range.
§ Increased L/DSO obtained in the remission period, compared with the L/DSO in the acute period.
 Pertinent data in each column are marked by a solid circle ( ).
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Fig. 1.  EOG fast oscillation (FO) and slow oscillation (SO) patterns in the acute and remission periods in both eyes of 
Patient 1 with Harada disease (47-year-old female).  R, right eye; L, left eye.  D, dark period; L, light period (horizontal 
axis).
showed some identical amplitude change.  Dated 
and occasional large amplitude changes were not 
taken into account (Inoue et al., 2003).
        Then the SO was recorded in all patients.  Be-
fore the SO recording, the patients were subjected 
to a 10-min pre-light adaptation in the same man-
ner as in the FO recording.  On the recording, 
where 20 min of darkness was followed by 20 min 
of illumination, EOG measurements were started 
40 s before the end of each 1-min period during 
the dark and light adaptations.  Six out of 10 EOG 
amplitudes were automatically averaged and re-
corded every 1 min during the SO measurement as 
in the FO recording.
        The SO shows a trough in the dark adaptation 
(dark trough) and a peak in the light adaptation 
(light peak) in response to dark and light periods 
of approximately 12.5 min each.  The L/DSO (the 
light peak/dark trough ratio of the SO) developed 
by Arden and others (1962) was automatically 
calculated as an SO parameter in the present 
survey.
        In this study, the calibration sensitivity for the 
pen recorder was 200 µV/division on the printer. 
The time constant of the amplifier was set at 3 s, 
and a high frequency cutoff of -3 dB was set at 20 
Hz for both FO and SO recordings.
        Pupillary dilation provides better control 
of retinal illumination levels, but prolongs the 
time for the EOG examination and may make 
the examination somewhat more uncomfortable 
for some patients.  Therefore, the FO and SO re-
cordings were performed with pupils undilated.
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Normal control eyes
Twenty-one fellow intact eyes of 21 patients with 
unilateral, ischemic central retinal vein occlusion 
(CRVO) previously reported by Inoue and others 
(2003) served as normal control eyes in the present 
survey.  Mean ± SD of the RfFO, dfFO and L/DSO 
were 125.9 ± 11.2% [n = 21], 168.9 ± 60.5 µV [n = 
21] and 1.93 ± 0.33 [n = 20], respectively in their 
FO and SO measurements (Inoue et al., 2003). 
Therefore, values over 114.7%, 108.4 µV and 1.6 
in the RfFO, dfFO and L/DSO, respectively were 
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Fig. 3.  Mutual relation to the dfFO of the EOG in the 
acute and remission periods in 12 eyes of 6 patients with 
Harada disease.  
Fig. 4.  Mutual relation to the L/DSO of the EOG in the 
acute and remission periods in 12 eyes of 6 patients with 
Harada disease.  
Fig. 2.  Mutual relation to the RfFO of the EOG in the 
acute and remission periods in 12 eyes of 6 patients with 
Harada disease.  
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Marks indicating each eye of each patient in Figs. 2 to 4:
 Patient 1
  right eye 
 Patient 1
  left eye 
 Patient 2
  right eye
 Patient 2
  left eye 
 Patient 3
  right eye
 Patient 3
  left eye
 Patient 4
  right eye
 Patient 4
  left eye 
 Patient 5
  right eye
 Patient 5
  left eye
 Patient 6
  right eye
 Patient 6
  left eye
tentatively regarded as those in the normal range in 
the present analysis.
Results
The FO and SO results obtained in the present 
study are summarized in Tables 2 to 4.
        Practical EOG FO and SO patterns in both eyes 
of Patient 1 (47-year-old female) are demonstrated 
in Fig. 1.  In this patient, reduced or deteriorated 
FO and SO patterns were observed in both eyes in 
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the acute period manifesting diffuse chorioretinal 
lesions before treatment.  Normal FO and SO 
patterns, however, were detected in both eyes in the 
remission period after systemic administration of 
corticosteroids reflecting ameliorated conditions in 
her fundi.
        Compared with normal control eyes, the RfFO, 
dfFO and L/DSO showed low values in 7 (58.3%), 10 
(83.3%) and 8 (66.7%) out of all 12 examined eyes 
of the 6 patients in the acute period, respectively 
(Tables 2 to 4).  In the remission period, values 
in the normal range were obtained in 12 (100%), 
11 (91.7%) and 8 (66.7%) out of 12 eyes of the 
patients in the RfFO, dfFO and L/DSO, respectively 
(Tables 2 to 4).
        In mutual relation to the RfFO in the acute and 
remission periods in the 6 patients (12 eyes), all 12 
eyes showed recovery values in the remission stage 
under corticosteroid therapy (Table 2, Fig. 2).
        In mutual relation to the dfFO in the acute and 
remission periods in the 6 patients (12 eyes), all 12 
eyes also showed recovery values in the remission 
period (Table 3, Fig. 3).
        However, in mutual relation to the L/DSO in 
the acute and remission periods in the 6 patients (12 
eyes), 4 out of 12 eyes (33.3%) showed no recovery 
in their values in the remission stage under the 
therapy (Table 4, Fig. 4).
Discussion
Concerning the origin and occurrence of the FO 
and SO potentials in which the outer layers of the 
retina, mainly the retinal pigment epithelium in its 
basal membrane are almost equally involved under 
the influence of choroidal disorders (Arden et al., 
1962; Steinberg et al., 1983; Joseph and Miller, 
1991), our FO-dominated pattern changes in the 
present study are not necessarily explainable, but 
it is of note that in 2 patients (2 eyes) with acute 
posterior multifocal placoid pigment epitheliopathy, 
one of the other chorioretinal diseases, almost 
the same tendency of recovery of their reduced 
FO patterns before treatment was observed after 
systemic administration of corticosteroids with 
amelioration of their ocular findings, although 
their highly fluctuated, irregular SO patterns 
before treatment showed no remarkable recovery 
in their patterns after the treatment by systemic 
corticosteroids (Tamai et al., 1997; Tamai, 2003).
        The FO may therefore be well reflected even 
in Harada disease, in contrast to the SO, although 
further observation is required using more Harada 
disease patients.
        Some physiological factors, such as age and 
sex, may influence the FO potential (Nakao et al., 
1995; Tamai et al., 1997).  Thus we need more 
prudent, long-term observations on the FO patterns 
in these chorioretinal diseases including Harada 
disease, considering these factors.
        In the present study, the visual outcome after 
the treatment by systemic corticosteroids was all 
well in the 12 eyes of the 6 patients.  This time, 
statistical analysis was not undertaken on the 
correlation between each parameter in the FO and 
SO recordings and corrected visual acuity in each 
patient’s eye both in the acute and remission period 
due to a small number of samples.  As for the visual 
prognosis, utility of a cone-dominated activity on 
the FO was pointed out in patients with unilateral, 
ischemic CRVO (Inoue et al., 2003).  Accordingly, 
although the background of macular functional 
disturbance in Harada disease is different from that 
in CRVO in etiology, such FO-dominated pattern 
changes in the present survey might be helpful 
for detecting the severity of macular functional 
disturbance and predicting the visual outcome for 
this entity.  Further work is required to investigate 
these aspects in more Harada disease patients.  
        Anyway, the results obtained in the present 
study may indicate that the FO is an effective exam-
ination method to detect the affected or ameliorated 
conditions in the outer layers of the retina and the 
choroid in Harada disease, in contrast to the SO. 
However, further observations are requested in 
more Harada disease patients, as described above.
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